drugset / Trial / NCT03151720

A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets

NCT03151720

Phase 1 Completed 28 enrolled Xian-Janssen Pharmaceutical Ltd.
RandomizedCrossoverOpen-labelOther

Summary

The purpose of this study is to establish the relative bioavailability of Xisimin (loratadine) compared to Clarityne in healthy participants receiving a single dose of 10 milligram (mg) under fasting condition as part of Cohort 1 and under fed condition as part of Cohort 2.

Timeline

Start
2017-06-01
Primary completion
2017-07-08
Completion
2017-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Loratadine Small molecule 10 mg Oral

Indications

No indication recorded.